Ognomy Sleep, announced the closing of a $20 million Series A financing round led by Catalyst Investors, with participation from Blue Heron Capital. The round also included new and follow-on investments from Impellent Ventures, LaunchNY, Excell and Upstate Biotech Ventures, University of Buffalo, and strategic partners who have supported the company’s […]
Sleep Disorders
LivaNova Shares Positive 12-Month Results From Obstructive Sleep Apnea Study
Recently published study results demonstrate the efficacy of LivaNova Plc’s aura6000 System in treating moderate to severe obstructive sleep apnea (OSA). Published in Annals of Internal Medicine, the full 12-month results from the company’s OSPREY randomized controlled trial (RCT) demonstrate the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality. Overall, the study authors concluded that pHGNS for OSA yielded clinically significant improvements versus […]
ProSomnus and MonitAir Collaborate to Enhance Connected Care for OSA
ProSomnus Sleep Technologies (“ProSomnus”), pioneer of Smart Sleep Medicine™, and MonitAir, LLC (“MonitAir”), the premier digital health and tele-monitoring platform for sleep medicine announced a collaboration to support connected, longitudinal and personalized care for patients with obstructive sleep apnea (OSA). Through this collaboration, healthcare providers who prescribe a ProSomnus RPMO₂ […]
New Study Shows Inspire Therapy Helps Reduce Hypoxic Burden
Inspire Medical Systems, Inc. participated in SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS) on June 14–17 in Baltimore, Maryland. SLEEP is the premier global forum for sleep medicine and research, jointly hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research […]
New Study: Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for Narcolepsy Type 1
New data presented by Takeda at SLEEP 2026 this week continues to build the case for oveporexton (TAK-861) as a potential disease-modifying treatment for narcolepsy type 1 (NT1). Oveporexton is designed to address the root cause of the disease, targeting the underlying orexin deficiency responsible for NT1. Results from two pivotal […]
Alkermes Presents Alixorexton and LUMRYZ Data at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
Alkermes plc announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD. The company will present 26 abstracts, including posters featuring LUMRYZ® (sodium oxybate) extended-release oral […]
Jazz Pharmaceuticals to Present Data at SLEEP 2026 Highlighting Effects of Xywav for Narcolepsy and Idiopathic Hypersomnia
Jazz Pharmaceuticals announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz’s continued focus on advancing treatment for rare and difficult-to-treat sleep […]
Vitacore Announces World-First Custom-Fit CPAP Mask Following Health Canada MDL Approval
Vitacore announced that it has received a Medical Device Licence (MDL) from Health Canada for FormFit™, the world’s first fully custom-fit medical-grade silicone CPAP mask. With regulatory approval secured, Vitacore is officially launching FormFit™ across Canada, direct-to-consumer at vitacore.com/formfit and through participating sleep clinics and healthcare providers nationwide. The proprietary […]
New Survey Results Explore the Complexity of Marijuana Use and Sleep
New survey results from the American Academy of Sleep Medicine explore the complex relationship between marijuana use and sleep. One-third (33%) of adults reported that their sleep is slightly or significantly better when they use marijuana. In contrast, 19% of adults reported either no impact (11%) or that their sleep is […]
Philips Expands DreamStation Access for Lower-Weight Patients
Philips announced that Philips Respironics DreamStation BiPAP AVAPS devices, which include S, T, S/T, and PC modes with AVAPS, are available for sale in the United States for new set-ups for patients with obstructive sleep apnea (OSA) and respiratory impairment, who are both >7 years of age and weighing 40-66lbs. The […]













